

Conversion of the Olivanic Acids into Antibiotics of the PS-5 Type: Use of a New Carboxy Protecting Group

By DAVID F. CORBETT and A. JOHN EGLINGTON*


(Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey RH3 7AJ)

Summary The syntheses of PS-5 (**1**) and analogues from the olivanic acids MM 17880 (**4**) and MM 13902 (**10**), including the use of a new carboxy protecting group, the *p*-methoxycarbonylbenzyl group, are reported together with the chemical elucidation of the stereochemistry at C-8 of the olivanic acids.

We have recently reported the structural elucidation of some new potent β -lactam antibiotics, the olivanic acids¹⁻³ possessing the 7-oxo-1-azabicyclo[3.2.0]hept-2-ene ring system. Some aspects of the chemistry of these antibiotics establishing their stereochemical interrelationships and their conversion into the antibiotics PS-5⁴ (**1**) and PS-7⁵ (**2**) are now described. We also report the use of a new carboxy protecting group, the *p*-methoxycarbonylbenzyl group.[†]

stereochemistry between C-6 and C-8 in MM 22381 (**16**) differs from that in MM 17880 (**4**) and MM 22380 (*cf.* **8**). Since the stereochemistry is (5*R*,6*R*) in (**4**) and (**8**), and (5*R*,6*S*) in (**16**)³ it follows that the configuration at C-8 is (*S*) in all the three metabolites. In the same way the C-8 stereochemistry of the other olivanic acids, MM 13902 (**10**), MM 22382 (**11**), and MM 22383 (**17**) was shown to be (*S*).


Hydride reduction (NaBH₄; aq. THF; † 3 °C) of the ethylidene group in (**12**) gave predominantly the *trans*- β -lactam (**3**) (30%) together with a little of the *cis*-compound (**18**) (ratio *ca.* 9:1). Hydrogenolysis (5% Pd-C; aq. dioxan) of the *p*-nitrobenzyl ester in (**3**) afforded the deoxy-derivative (**1**) (PS-5), isolated as its sodium salt. The dehydro-derivative (**2**) (PS-7) was obtained by a similar sequence of reactions from MM 13902 (**10**).



(1) R¹=H, R²=CH₂CH₂NHCOMe

(2) R¹=H, R²=CH=CHNHCOMe

(3) R¹=PNB, R²=CH₂CH₂NHCOMe



(4) R¹=H, R²=HO₃S; MM 17880


(5) R¹=PNB, R²=EtO₃S

(6) R¹=Na, R²=NaO₃S

(7) R¹=PNB, R²=MeSO₂


(8) R¹=PNB, R²=H

(9) R¹=PMCB, R²=NaO₃S



(10) R=HO₃S; MM 13902


(11) R=H; MM 22382



(12) R¹=PNB, R²=Me, R³=H

(13) R¹=PNB, R²=H, R³=Me

(14) R¹=PMCB, R²=Me, R³=H




(15) R¹=PNB, R²=MeSO₂

R³=CH₂CH₂NHCOMe

(16) R¹=R²=H, R³=CH₂CH₂NHCOMe

(17) R¹=R²=H, R³=CH=CHNHCOMe



(18) R¹=PNB, R²=CH₂CH₂NHCOMe


(19) R¹=CH₂Ph, R²=CH=CHNHCOMe

(20) R¹=PNB, R²=CH=CHNHCOMe

(21) R¹=PMCB, R²=CH₂CH₂NHCOMe

(22) R¹=H, R²=CH₂CH₂NHCOMe

(23) R¹=H, R²=CH=CHNHCOMe



(24) R=CH₂Ph

(25) R=PNB

PNB = CH₂C₆H₄NO₂-*p*
PMCB = CH₂C₆H₄CO₂Me-*p*

PNB = CH₂C₆H₄NO₂-*p*
PMCB = CH₂C₆H₄CO₂Me-*p*

The ethyl sulphate *p*-nitrobenzyl carboxylate (**5**) of MM 17880 was prepared from the corresponding disodium salt (**6**)² by esterification with *p*-nitrobenzyl bromide (DMF; † r.t.), ion pair extraction [PhCH₂(Me)₂(C₁₆H₃₃)-N⁺Cl⁻; CH₂Cl₂-H₂O], and alkylation (Et₃O⁺BF₄⁻; CH₂Cl₂). Elimination of sulphate from (**5**) (K₂CO₃; DMF; r.t.) gave the (*E*)-ethylidene derivative (**12**) (45%). Similarly the mesylate (**7**), derived (MeSO₂Cl; Et₃N; CH₂Cl₂) from the *p*-nitrobenzyl ester (**8**) of MM 22380,³ afforded the (*E*)-ethylidene derivative (**12**), but the mesylate (**15**), derived from MM 22381 (**16**)³ yielded the (*Z*)-ethylidene derivative (**13**). Assuming the reactions proceed *via* an *E2* elimination in the normal *anti*-manner it follows that the relative

In contrast to hydride reduction, catalytic hydrogenation of the 6-ethylidene derivatives gave predominantly the *cis*-6-ethyl isomer. Thus for example (**24**), derived from the monobenzyl ester of MM 13902, gave (H₂; PtO₂; EtOAc; 24 h) largely the *cis*-6-ethyl derivative (**19**) together with a little of the corresponding *trans*-6-ethyl isomer (*ca.* 4:1). Under the same conditions the *p*-nitrobenzyl ester (**25**) failed to give the desired *cis*-6-ethyl derivative (**20**) in acceptable yield. Attempts at removing the benzyl group from (**19**) also proved unsuccessful, and as quantities of the carboxylic acid were required for biological evaluation another protecting group was developed.

p-Methoxycarbonylbenzyl acetate is known to be cleaved electrochemically⁶; thus the use of the *p*-methoxycarbonylbenzyl[†] esters of the olivanic acids was investigated. Accordingly, the PMCB ester of MM 17880 (**9**),

† PMCB = *p*-methoxycarbonylbenzyl; PNB = *p*-nitrobenzyl; DMF = dimethylformamide; THF = tetrahydrofuran.

‡ New compounds reported were satisfactorily characterised by microanalytical and/or spectroscopic data.

prepared by alkylation of the disodium salt (**6**) with methyl 4-bromomethylbenzoate, was converted into the ethylidene derivative (**14**). Hydrogenation yielded the *cis*-6-ethyl derivative (**21**) (30%). Cleavage of the ester group was effected by reduction at a Hg cathode (-1.9 V vs standard calomel electrode) in a divided cell (Pt anode, 0.1 M $\text{Bu}^n_4\text{-NBF}_4$; DMF). After removal of DMF the catholyte was partitioned between CH_2Cl_2 and aqueous NaBF_4 to afford the sodium salt of (**22**) (*6-epi* PS-5) in the aqueous layer. The sodium salt of (**22**) was purified by chromatography on

Biogel P-2. A similar sequence of reactions from MM 13902 (**10**) gave the sodium salt corresponding to the dehydro-derivative (**23**) (*6-epi* PS-7).

All four derivatives (**1**), (**2**), (**22**), and (**23**) showed a high level of antibacterial activity. Racemic (**1**) and (**22**) have been prepared in these laboratories by a totally synthetic route.⁷

(Received, 6th August 1980, Com 868)

¹ A. G. Brown, D. F. Corbett, A. J. Eglinton, and T. T. Howarth, *J. Chem. Soc., Chem. Commun.*, 1977, 523

² D. F. Corbett, A. J. Eglinton, and T. T. Howarth, *J. Chem. Soc., Chem. Commun.*, 1977, 954

³ A. G. Brown, D. F. Corbett, A. J. Eglinton, and T. T. Howarth, *J. Antibiotics*, 1979, **32**, 961

⁴ K. Okamura, S. Hirata, Y. Okumura, Y. Fukagawa, Y. Shimauchi, K. Kouno, T. Ishikura, and J. Lein, *J. Antibiotics*, 1978, **31**, 480

⁵ European Patent Application No. 78100993.1

⁶ J. P. Coleman, H. G. Gilde, J. H. P. Utley, and B. C. L. Weedon, *Chem. Commun.*, 1970, 738

⁷ J. H. Bateson, R. I. Hickling, P. M. Roberts, T. C. Smale, and R. Southgate, *J. Chem. Soc., Chem. Commun.*, 1980, following communication